LENZ 治疗法根据扎实的Q3结果和积极的试验数据增加库存,而Larimar则降低前景。 LENZ Therapeutics boosts stock on strong Q3 results and positive trial data, while Larimar lowers outlook.

分析家们提高了LENZ治疗法的收入估计数,引用了2025年Q3成果的有力数字,收入为1 250万美元,远远超出预期,损失也比预测的要小。 Analysts have raised their earnings estimates for LENZ Therapeutics, citing strong Q3 2025 results with revenue of $12.5 million, far exceeding expectations, and a narrower loss than forecast. 多个公司提升了评级和价格目标,达成了协商一致的“机动购买”和平均目标为56.40美元。 Multiple firms upgraded their ratings and price targets, with a consensus “Moderate Buy” and an average target of $56.40. 该公司在第三阶段试验中开发了预视疗法,进行了内部采购。 The company, developing presbyopia treatments in Phase III trials, saw insider purchases. 与此形成对照的是,拉里马尔治疗学降低了其前景,分析家预测2025年和2026年损失会更深,尽管目前正在对罕见疾病的治疗进行第二阶段试验。 In contrast, Larimar Therapeutics lowered its outlook, with analysts projecting deeper losses in 2025 and 2026, despite ongoing Phase 2 trials for a rare disease treatment.